Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. Following its acquisition of OneOme in November 2025, Tempus has fully integrated these capabilities to expand its comprehensive precision medicine portfolio, bridging a critical gap between genomic tumor profiling and how a patient's body actually processes treatment.

"Answering the urgent demand for immediate, reliable medication safety insights is a clinical imperative, particularly in oncology care," said Tom Schoenherr, CEO of Diagnostics at Tempus. “By bringing OneOme’s robust pharmacogenomics platform into the Tempus ecosystem and offering both rapid single-gene and broad multi-gene panels, we are providing clinicians with a more holistic view of the patient and actively closing this safety gap.”

The national launch introduces OneOme’s flagship RightMed® Comprehensive test, a 27-gene germline PGx laboratory developed test designed to analyze a patient’s inherited genetic traits, alongside standalone single-gene DPYD and UGT1A1 testing. These options evaluate how a patient’s unique genetic profile may influence their response, toxicity risk or optimal dosage across a broad spectrum of therapies. Recent FDA labeling updates recommend DPYD testing prior to administering common fluoropyrimidine therapies¹— treatments where nearly 30% of patients experience severe, and sometimes fatal, toxicities².

Whether providers order the comprehensive 27-gene panel or the targeted single-gene assays, the testing provides a rapid turnaround time, delivering results in under 5 days on average from sample receipt. This testing solution is seamlessly integrated into the broader Tempus ecosystem, allowing clinicians to evaluate drug-gene interactions alongside both tissue and liquid biopsy sequencing directly at the point of care.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ launch of OneOme pharmacogenomics testing. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

^1 Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. News release. FDA. February 5, 2026. Accessed February 6, 2026. https://tinyurl.com/367ms26w.

^2 Lesnjakovic L, Ganoci L, Bilic I, et al. DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics. 2023 Jan;24(2):93-106.